OBJECTIVES: Estimate HRU and DME for adult women with AD. METHODS: A retrospective cross-sectional case-control design using 2006 MEPS. Females > 17 years who reported AD were selected. A control group was created using propensity score matching.  The data was fitted to poisson (P), negative binomial (NB), zero-inflated poisson (ZIP), and zero-inflated negative binomial (ZINB) models. A plot of residuals was examined and the plot closest to zero was selected as the best fitting model. To calculate the HRU attributable to AD, the unadjusted mean number of visits for those without AD was multiplied by the regression coefficient for AD from the multivariate regression minus the unadjusted mean number of visits for those without AD.  To estimate DME, a generalized linear model (GLM) was estimated with a Park’s test to select the appropriate variance function after which the incremental expenditure was calculated by the method of recycled predictions. All analyses incorporated the MEPS sampling and variance adjustment weights to ensure nationally representative sample. All the component expenditures were summed and multiplied by the number of females who reported AD in 2006 to get the national estimate of direct medical expenditures. RESULTS: The annual number of inpatient, emergency room, outpatient, and office based visits attributable to AD was 0.03, 0.07, 0.34, AND 4.3 respectively. There were 0.05 home health days and 8.47 prescriptions including refills obtained by adult women with AD. The estimated national annual direct COI associated with AD among adult women was $26.52 billion.  This was calculated by multiplying the per-person total incremental medical expenditure associated with AD among female adults ($2,143.16) with the prevalence of AD (12,374,189). CONCLUSIONS: Inpatient expenditures accounted for the largest proportion of DME followed by office based and prescription expenditures. Adult women with AD have a significant societal burden.